Clinical Trials Browser

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

1 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT07018622 2026-03-11

DAPA-ARMOR

Phase 2 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT07382544 2026-02-25

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Phase 1 Recruiting

36 enrolled

Other solid neoplasm

Advanced Cancer

NCT06331559 2026-02-09

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06560632 2026-01-16

POLAR

Phase 1 Terminated

26 enrolled 14 charts

Other solid neoplasm

Advanced Solid Tumor

NCT00777582 2026-01-13

Phase I Comparative Bioavailability Study

Phase 1 Active not recruiting

197 enrolled

Other solid neoplasm

Solid Tumors

NCT05240898 2025-12-18

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Completed

116 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05522491 2025-12-11

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Phase 2 Not yet recruiting

30 enrolled

Other solid neoplasm

Solid Tumor

NCT04972110 2025-10-30

ATTACC

Phase 1/2 Terminated

156 enrolled 19 charts

Other solid neoplasm

Advanced Solid Tumor, Adult

NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

Phase 2 Recruiting

56 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

NCT04123366 2025-03-17

MK-7339-007

Phase 2 Active not recruiting

300 enrolled

Other solid neoplasm

Solid Tumors

NCT06686745 2025-01-07

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1 Recruiting

130 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Phase 2 Recruiting

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06525298 2024-09-19

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Phase 1/2 Recruiting

144 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT00782574 2023-12-21

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

Phase 1 Completed

57 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02588105 2022-09-19

AToM

Phase 1 Completed

84 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Phase 1 Terminated

44 enrolled

Other solid neoplasm

Solid Tumors

NCT03057145 2021-09-02

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1 Completed

29 enrolled

Other solid neoplasm

Solid Tumor

NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

Phase 2 Completed

23 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02430311 2019-07-31

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Phase 1 Completed

36 enrolled 24 charts

Other solid neoplasm

Advanced Solid Tumours

NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

Phase 1 Completed

48 enrolled

Other solid neoplasm

Malignant Solid Tumors

Clinical Trials

LuPARP

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

DAPA-ARMOR

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

POLAR

Phase I Comparative Bioavailability Study

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

ATTACC

Olaparib in Patients With HRD Malignant Mesothelioma

MK-7339-007

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

AToM

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Olaparib in People With Malignant Mesothelioma

The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan